JAMA

JAMA
Audio Summaries

Every issue of JAMA moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

150 audio summariesNLM Catalog

Recent summaries

The latest articles summarized from JAMA.

Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology.

Nov 19, 2026

This case series of 21 former American football players examined whether plasma endogenously cleaved microtubule-binding region tau (eMTBR-tau) could serve as an in vivo biomarker for chronic traumatic encephalopathy (CTE) tau tangle pathology, which currently can only be confirmed at autopsy. Plasma eMTBR-tau was significantly higher in CTE-positive donors than CTE-negative donors, and highest in high-stage CTE with comorbid Alzheimer disease neuropathologic change, with levels also correlating with neuropathologic tau burden. The authors conclude that plasma eMTBR-tau may be a feasible candidate biomarker for high-stage CTE, though larger validation studies are needed to establish diagnostic accuracy and specificity.

Medical Imaging and Pediatric and Adolescent Brain Tumor Risk.

Nov 19, 2026

This retrospective cohort study of about 3.7 million children in six US health systems and Ontario, Canada, asked whether cumulative brain radiation dose from medical imaging is associated with later brain or central nervous system tumors. The authors found a dose-related increase in risk, with hazard ratios rising from 1.12 for under 1 mGy to 3.85 for 150 mGy or more, and stronger associations for aggressive tumor types. They estimated roughly 1 excess brain tumor per 1,266 head CT examinations by age 21, supporting careful justification and dose minimization for pediatric imaging that uses ionizing radiation.

Toward a Healthier Future Through Obesity Prevention and Care: The JAMA Summit Report on Obesity.

Nov 17, 2026

This JAMA Summit report asks how to reduce the growing burden of obesity, which affects over 1 billion people worldwide and nearly half of U.S. adults. The authors conclude that existing prevention measures have been insufficient and that new effective medications, while promising, cannot solve the problem alone. They call for coordinated, multisector action, including food and school policies, drug evaluation modernization, payment reform, multidisciplinary care models, and efforts to reduce stigma and health inequities.

A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology.

Nov 16, 2026

This cross-sectional study asked whether a scalable plasma immunoassay for endogenously cleaved microtubule-binding region tau (eMTBR-tau) can detect neurofibrillary tangle pathology, as mass spectrometry-based measures have shown promise but are hard to scale. In 728 participants across autopsy and tau-PET cohorts, plasma eMTBR-tau rose sharply with advanced Braak stages (about 25- to 50-fold higher at stage VI vs. stages I-II in autopsy cohorts, and 60-fold higher at PET stages V-VI vs. stage 0), with strong correlations to regional tau-PET and to mass spectrometry measurements (ρ = 0.93). The immunoassay discriminated tau-PET positivity well (AUC 0.96-0.99), providing proof of principle that it can serve as a marker of advanced tau tangle pathology.

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.

Nov 15, 2026

This phase 3, double-blind, placebo-controlled trial asked whether once-weekly subcutaneous ribupatide, a dual GIP/GLP-1 receptor agonist, produces meaningful weight loss in adults with overweight or obesity (without diabetes) in China. Over 48 weeks, participants receiving 2, 4, or 6 mg ribupatide lost 10.7%, 16.4%, and 17.7% of their body weight, respectively, versus 1.4% with placebo, and 69–88% of treated participants achieved at least 5% weight loss compared with 16% on placebo. Gastrointestinal adverse events were the most common side effects (47–63% vs 23% with placebo), but few participants discontinued treatment because of them.

Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial.

Nov 15, 2026

In this phase 3 randomized, double-blind trial, the authors asked whether once-weekly tirzepatide, added to lifestyle intervention, would safely reduce BMI in adolescents aged 12 to under 18 with obesity or overweight plus at least one obesity-related complication. Among 160 participants followed for 72 weeks, tirzepatide produced an 18.5% BMI reduction versus a 0.5% increase with placebo (estimated difference -19.0 percentage points), with 79.6% of treated patients achieving at least a 5% BMI reduction. The most common adverse events were mild-to-moderate gastrointestinal effects.

Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology.

Nov 13, 2026

This case-control study asked whether biofluid eMTBR-tau243, a mass spectrometry-measured cleaved tau fragment, specifically reflects mixed 3R/4R tau pathology across tauopathies. Across 229 participants, CSF and plasma eMTBR-tau243 were elevated in AD, in symptomatic FTLD-MAPT carriers with mixed 3R/4R pathology, and in high-stage CTE (plasma AUC 0.97 for stages III-IV versus controls), but not in most pure 4R tauopathies such as PSP and CBD. The authors conclude that eMTBR-tau243 may be a promising diagnostic biomarker for CTE and other mixed tauopathies beyond AD, though larger validation cohorts are needed.

Treatment of Acute Ischemic Stroke: A Review.

Nov 12, 2026

This review by Albers and Heit summarizes current management of acute ischemic stroke, addressing how to treat patients with disabling symptoms in a timely way. The authors conclude that intravenous thrombolysis (tenecteplase or alteplase) is first-line within 4.5 hours of onset, extendable up to 9 hours or 24 hours in selected cases with perfusion imaging, while endovascular thrombectomy is recommended for large vessel occlusion within 6 to 24 hours, with thrombectomy yielding roughly a 20% absolute increase in functional independence.

Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial.

Nov 12, 2026

This phase 3 randomized trial asked whether izalontamab brengitecan, an EGFR/HER3 bispecific antibody-drug conjugate, improves outcomes versus physician-selected chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma that progressed after first-line PD-1/PD-L1 inhibitor plus platinum chemotherapy. In 497 patients across 80 Chinese hospitals, izalontamab brengitecan significantly prolonged progression-free survival (median 4.17 vs 1.97 months; HR 0.50) and overall survival (median 9.79 vs 7.20 months; HR 0.63), at the cost of more frequent grade 3 or higher treatment-related adverse events (85.1% vs 59.3%, mostly hematologic). The authors conclude that izalontamab brengitecan may serve as a new second-line treatment for this population in China.

HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial.

Nov 11, 2026

This phase 1 nonrandomized trial asked whether a single oral dose of HOPO 14-1, an orally administered actinide chelator, is safe and tolerable in healthy adults, and how it is absorbed and excreted. In 42 participants across seven dose levels (100 mg to 7500 mg), there were no serious adverse events or dose-limiting toxicities, with mild-to-moderate gastrointestinal effects (mainly diarrhea and vomiting) becoming most prominent at the highest doses. The drug was rapidly absorbed, showed greater-than-proportional increases in exposure at higher doses, and was eliminated mainly in feces, with minimal urinary excretion.

Listen to JAMA

14-day free trial. Every new article, summarized in ~3 minutes.